Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 5/20 | 0.55 |
| ▸ | DYRK1B | Q9Y463 | 5/20 | 0.55 |
| ▸ | DYRK2 | Q92630 | 3/20 | 0.55 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.54 |
| ▸ | CLK1 | P49759 | 3/20 | 0.54 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.54 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.54 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.54 |
| ▸ | CLK2 | P49760 | 1/20 | 0.54 |
| ▸ | CLK3 | P49761 | 1/20 | 0.54 |
| ▸ | PLK4 | O00444 | 2/20 | 0.53 |
| ▸ | PLK1 | P53350 | 2/20 | 0.53 |
| ▸ | RET | P07949 | 1/20 | 0.53 |
| ▸ | FLT3 | P36888 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.53 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.52 |
| ▸ | PIM1 | P11309 | 1/20 | 0.52 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6392297 | 1.00 | DYRK1A (0.55) | DYRK1ADYRK1BDYRK2PDGFRBCLK1 | |
| SCHEMBL7397358 | 0.86 | PDGFRB (0.57) | PDGFRBPLK4PLK1RETFLT3 | |
| SCHEMBL7397362 | 0.86 | PDGFRB (0.57) | PDGFRBPLK4PLK1RETFLT3 | |
| SCHEMBL7405700 | 0.86 | PDGFRB (0.57) | PDGFRBPLK4PLK1RETFLT3 | |
| SCHEMBL6395508 | 0.85 | LRRK2 (0.58) | DYRK1ADYRK1BDYRK2PDGFRBCLK1 | |
| SCHEMBL6392018 | 0.85 | PLK4 (0.59) | DYRK1ADYRK1BDYRK2PDGFRBCLK1 | |
| SCHEMBL6392015 | 0.85 | PLK4 (0.59) | DYRK1ADYRK1BDYRK2PDGFRBCLK1 | |
| SCHEMBL6391109 | 0.85 | CDK2 (0.55) | DYRK1ADYRK1BDYRK2CLK1CSNK2A2 | |
| SCHEMBL6395513 | 0.85 | LRRK2 (0.58) | DYRK1ADYRK1BDYRK2PDGFRBCLK1 | |
| SCHEMBL6391111 | 0.85 | CDK2 (0.55) | DYRK1ADYRK1BDYRK2CLK1CSNK2A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2908843-B1 | TREATING CANCER | AGENCY SCIENCE TECH & RES (SG) | 2019-09-04 | — | — | EP | claimed |
| US-9889180-B2 | Method of treating cancer | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-02-13 | — | — | US | claimed |
| US-20150258175-A1 | METHOD OF TREATING CANCER | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-09-17 | — | — | US | claimed |
| EP-2908843-A1 | METHOD OF TREATING CANCER | Agency For Science, Technology And Research (SG) | 2015-08-26 | — | — | EP | claimed |
| WO-2014077784-A1 | METHOD OF TREATING CANCER | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2014-05-22 | — | — | WO | claimed |
| US-6855730-B2 | 3-methylidenyl-2-indolinone modulators of protein kinase | SUGEN, INC. (US) | 2005-02-15 | — | — | US | claimed |
| US-20040024010-A1 | 3-methylidenyl-2-indolinone modulators of protein kinase | SUGEN, INC. | 2004-02-05 | — | — | US | claimed |
| EP-2908843-B1 | TREATING CANCER | AGENCY SCIENCE TECH & RES (SG) | 2019-09-04 | — | — | EP | disclosed |
| US-6855730-B2 | 3-methylidenyl-2-indolinone modulators of protein kinase | SUGEN, INC. (US) | 2005-02-15 | — | — | US | disclosed |
| US-20040024010-A1 | 3-methylidenyl-2-indolinone modulators of protein kinase | SUGEN, INC. | 2004-02-05 | — | — | US | disclosed |
| US-6531502-B1 | Antitumor | SUGEN, INC. | 2003-03-11 | — | — | US | disclosed |
| WO-2000008202-A9 | 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE | SUGEN INC (US) | 2000-07-27 | — | — | WO | disclosed |
| WO-2000008202-A2 | 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE | SUGEN, INC. (US) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024010-A1 | 3-methylidenyl-2-indolinone modulators of protein kinase | DMPK, MAP4K3, MAP3K20 | DYRK1A 439/4885DYRK1B 456/4885DYRK2 469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.